Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
暂无分享,去创建一个
Zhi-xiang Shen | E. Leroy | H. Schran | O. Yin | V. Sethuraman | Yanfeng Wang | Li Zhou | G. Rivière | C. Dutreix | Q. Yin
[1] Nicolas Widmer,et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. , 2006, British journal of clinical pharmacology.
[2] Allan H Friedman,et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Eichelbaum,et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study , 2005, Clinical pharmacology and therapeutics.
[4] A. Racine‐Poon,et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. , 2005, British journal of clinical pharmacology.
[5] P. Pibarot,et al. Modulation of Metoprolol Pharmacokinetics and Hemodynamics by Diphenhydramine Coadministration during Exercise Testing in Healthy Premenopausal Women , 2005, Journal of Pharmacology and Experimental Therapeutics.
[6] C. Corless,et al. State-of-the Art Therapy for Gastrointestinal Stromal Tumors , 2005, Cancer investigation.
[7] W. Jusko,et al. The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate , 2004, Pharmacotherapy.
[8] C. Meisel,et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics , 2004, Clinical pharmacology and therapeutics.
[9] M. Egorin,et al. Effect of St John's Wort on imatinib mesylate pharmacokinetics , 2004, Clinical pharmacology and therapeutics.
[10] R. Capdeville,et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects , 2004, Cancer Chemotherapy and Pharmacology.
[11] A. Racine‐Poon,et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Capdeville,et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects , 2004, Cancer Chemotherapy and Pharmacology.
[13] C. Huber,et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia , 2003, British Journal of Cancer.
[14] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[15] M. Hersberger,et al. Genetic polymorphisms of CYP2D6 in Chinese mainland. , 2002, Chinese Medical Journal.
[16] F. Tse,et al. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[17] M Schwab,et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.
[18] Shiew-Mei Huang,et al. Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential‐toward a consensus , 2001 .
[19] J B Houston,et al. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. , 2001, British journal of clinical pharmacology.
[20] M Schwab,et al. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. , 2000, Pharmacogenetics.
[21] M. Lai,et al. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes , 1999, Clinical pharmacology and therapeutics.
[22] J. Brockmöller,et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.
[23] M. Ingelman-Sundberg,et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.
[24] G. Tucker,et al. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. , 1985, British journal of clinical pharmacology.
[25] Malcolm Rowland,et al. Kinetics of drug-drug interactions , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[26] T. Buclin,et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. , 2006, British journal of clinical pharmacology.
[27] Peter Lloyd,et al. Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.
[28] Ulrich M. Zanger,et al. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[29] L. D. Bradford,et al. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.
[30] M. Lennard. The polymorphic oxidation of beta-adrenoceptor antagonists. , 1989, Pharmacology & therapeutics.
[31] G. Tucker,et al. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. , 1986, Clinical pharmacokinetics.
[32] G. Tucker,et al. The Polymorphic Oxidation of β-Adrenoceptor Antagonists , 1986 .